Citations

Showing 10 of 108152 citations.

Perioperative Opioid Consumption and Clinical Outcomes in Surgical Patients With a Pre-existing Opioid-Based Intrathecal Drug Delivery System
D’Souza, Ryan S., Warner, Matthew A., Olatoye, Oludare O., Langford, Brendan J., Bruns, Danette L., Schroeder, Darrell R., Mauck, William D., Schaefer, Kalli K., Warner, Nafisseh S., Schroeder, Darrell R. , D’Souza, Ryan S. , D'Souza, Ryan S , Schroeder, Darrell , D’Souza, Ryan S., Warner, Matthew A., Olatoye, Oludare O., Langford, Brendan J., Bruns, Danette L., Schroeder, Darrell R., Mauck, William D., Schaefer, Kalli K., Warner, Nafisseh S.

Mayo Clinic

Anesthesia & Analgesia | July 14, 2021 | Volume: 134 | Issue: 1 | Pages: 35-43

10.1213/ane.0000000000005662 | PMID 34260427 Get It

BACKGROUND: Intrathecal drug delivery systems (IDDS) have been utilized for over 3 decades for management of chronic pain and spasticity. Patients with IDDS may present for surgical procedures unrelated to the IDDS device, although data are limited regarding perioperative outcomes. METHODS: This is a historical matched cohort study conducted between January 1, 2007 and December 31, 2016 of patients with an opioid-based IDDS versus matched control patients undergoing surgery excluding interventional pain procedures. Patients in the IDDS group were matched with up to 2 patients without an IDDS. Multivariable regression analyses were utilized to assess differences in the primary outcome of cumulative perioperative opioid consumption (ie, intraoperative and postanesthesia care unit [PACU] opioid consumption), and opioid consumption during the first 24 and 72 postoperative hours. Postoperative clinical outcomes were also assessed including escalating oxygen requirements, naloxone administration, pain-sedation mismatch, and perioperative pain service consultation. RESULTS: A total of 321 surgeries were included, 112 with IDDS and 209 controls, with median (interquartile range [IQR]) age of 57 (49–64) years. Compared to matched controls, patients with an IDDS had greater perioperative opioid consumption (median [IQR] oral morphine milligram equivalents [OME] of 110 [60–163] vs 93 [IQR, 53–142]; adjusted multiplicative increase 1.28 [95% confidence interval {CI}, 1.03–1.59]; P = .026). IDDS patients also had greater opioid consumption in the first 24 and 72 postoperative hours (multiplicative increases of 2.23 [95% CI, 1.36–3.63], P = .001, and 2.46 [95% CI, 1.41–4.32], P = .002, respectively). There were no significant differences in postoperative oxygen requirements, naloxone administration, or pain-sedation mismatch. Inpatient pain medicine consultation was more frequent in IDDS patients compared to controls (51.8% vs 6.2%; P < .001). CONCLUSIONS: Patients with opioid-based IDDS received more perioperative opioids and were more likely to receive postoperative pain service consultation compared to matched controls. There were no significant differences in clinical safety outcomes, suggesting tolerance for higher opioid doses. Further research is warranted to optimize perioperative outcomes in those with IDDS.
Facial Dysmorphology in Saethre-Chotzen Syndrome
Junn, Alexandra , Dinis, Jacob , Lu, Xiaona , Forte, Antonio J. , Mozaffari, Mohammad Ali , Phillips, Sarah , Alonso, Nivaldo , Persing, John A. , Alperovich, Michael , Forte, Antonio Jorge , Lopez, Joseph

Mayo Clinic

Journal of Craniofacial Surgery | July 14, 2021 | Volume: 32 | Issue: 8 | Pages: 2660-2665

10.1097/scs.0000000000007910 | PMID 34727468 Get It

Purpose: Classic features of Saethre-Chotzen syndrome (SCS) described in the literature include a prominent nasal bridge, eyelid ptosis, telorbitism, maxillary hypoplasia, and mandibular prognathism. The purpose of this study was to evaluate objectively the bony features of SCS. Methods: Preoperative computer tomography scans of 15 SCS patients, 23 normal controls, 13 bicoronal nonsyndromic, and 7 unicoronal nonsyndromic craniosynostosis patients were included for analysis. Unaffected controls and nonsyndromic patients were age- and sex-matched to SCS patients. Morphometric cephalometrics were analyzed using three-dimensional computer tomography reconstructions. Mann–Whitney U were used to compare facial measurements between SCS and normal and nonsyndromic craniosynostosis controls. Results: Telorbitism was present in bicoronal SCS patients only (P = 0.04) but absent in the unicoronal and bicoronal/metopic cohorts. The angle of the nasal bone relative to the sella was not different between SCS and controls (P = 0.536), although the angle of the nasal bone relative to the forehead was decreased in SCS by 15.5° (P < 0.001). Saethre-Chotzen syndrome had a 2.6° maxillary retrusion relative to controls (P = 0.03). In addition, SCS patients aged 4 to 7 months had a wider (39.34 versus 35.04, P = 0.017) and anteroposteriorly foreshortened (32.12 versus 35.06, P = 0.039) maxilla. There was no difference in mandibular prognathism among SCS patients as measured by the sella-nasion-B point angle compared to controls (P = 0.705). Conclusions: Despite classic descriptions, on morphometric analysis SCS patients did not demonstrate consistency across all suture subtypes in terms of telorbitism, a broad nasal bridge, or mandibular prognathism. Rather, SCS subtypes of SCS based on suture pathology more closely resemble nonsyndromic patients.
Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology
Petraina, Alexandra , Nogales, Cristian , Krahn, Thomas , Mucke, Hermann AM , Lüscher, Thomas F. , Fischmeister, Rodolphe , Kass, David A. , Burnett, John C. , Schmidt, Harald , Mucke, Hermann , Hobbs, Adrian J , Schmidt, Harald H H W

Mayo Clinic

Cardiovascular Research | July 14, 2021 | Volume: 118 | Issue: 9 | Pages: 2085-2102

10.1093/cvr/cvab240 | PMID 34270705 Get It

Abstract Mechanism-based therapy centred on the molecular understanding of disease-causing pathways in a given patient is still the exception rather than the rule in medicine, even in cardiology. However, recent successful drug developments centred around the second messenger cyclic guanosine-3′-5′-monophosphate (cGMP), which is regulating a number of cardiovascular disease modulating pathways, are about to provide novel targets for such a personalized cardiovascular therapy. Whether cGMP breakdown is inhibited or cGMP synthesis is stimulated via guanylyl cyclases or their upstream regulators in different cardiovascular disease phenotypes, the outcomes seem to be so far uniformly protective. Thus, a network of cGMP-modulating drugs has evolved that act in a mechanism-based, possibly causal manner in a number of cardiac conditions. What remains a challenge is the detection of cGMPopathy endotypes amongst cardiovascular disease phenotypes. Here, we review the growing clinical relevance of cGMP and provide a glimpse into the future on how drugs interfering with this pathway may change how we treat and diagnose cardiovascular diseases altogether.
Cancer Misinformation and Harmful Information on Facebook and Other Social Media: A Brief Report
Johnson, Skyler B. , Parsons, Matthew, Dorff, Tanya B. , Moran, Meena S. , Akerley, Wallace , Bauman, Jessica R. , Spratt, Daniel E. , Bylund, Carma L. , Swire‐Thompson, Briony , Scherer, Laura D. , Spratt, Daniel E , Parsons, Matthew, Ward, John Headley , Cohen, Stacey A. , Hubbard, Joleen M. , Onega, Tracy , Tward, Jonathan D. , Fagerlin, Angela

Mayo Clinic

JNCI: Journal of the National Cancer Institute | July 14, 2021 | Volume: 114 | Issue: 7 | Pages: 1036-1039

10.1093/jnci/djab141 | PMID 34291289 Get It

Abstract There are few data on the quality of cancer treatment information available on social media. Here, we quantify the accuracy of cancer treatment information on social media and its potential for harm. Two cancer experts reviewed 50 of the most popular social media articles on each of the 4 most common cancers. The proportion of misinformation and potential for harm were reported for all 200 articles and their association with the number of social media engagements using a 2-sample Wilcoxon rank-sum test. All statistical tests were 2-sided. Of 200 total articles, 32.5% (n = 65) contained misinformation and 30.5% (n = 61) contained harmful information. Among articles containing misinformation, 76.9% (50 of 65) contained harmful information. The median number of engagements for articles with misinformation was greater than factual articles (median [interquartile range] = 2300 [1200-4700] vs 1600 [819-4700], P = .05). The median number of engagements for articles with harmful information was statistically significantly greater than safe articles (median [interquartile range] = 2300 [1400-4700] vs 1500 [810-4700], P = .007).
Approach to the Patient With Adrenal Incidentaloma
Prete, Alessandro , Bancos, Irina , Prete, Alessandro , Bancos, Irina

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | July 14, 2021 | Volume: 106 | Issue: 11 | Pages: 3331-3353

10.1210/clinem/dgab512 | PMID 34260734 Get It

Abstract Adrenal tumors are commonly discovered incidentally on cross-sectional abdominal imaging performed for reasons other than adrenal mass. Incidence of adrenal tumors increased 10-fold in the past 2 decades, with most diagnosed in older adults. In any patient with a newly discovered adrenal mass, determining whether the adrenal mass is malignant and whether it is hormonally active is equally important to guide the best management. Malignancy is diagnosed in 5% to 8% of patients with adrenal tumors, with a higher risk in young patients, if history of extra-adrenal malignancy, in those with large adrenal tumors with indeterminate imaging characteristics, and in bilateral adrenal tumors. Although overt hormone excess is uncommon in adrenal incidentalomas, mild autonomous cortisol secretion can be diagnosed in up to 30% to 50% of patients. Because autonomous cortisol secretion is associated with increased cardiovascular morbidity and metabolic abnormalities, all patients with adrenal incidentalomas require work up with dexamethasone suppression test. Management of adrenal tumors varies based on etiology, associated comorbidities, and patient’s preference. This article reviews the current evidence on the diagnosis and evaluation of patients with adrenal mass and focuses on management of the most common etiologies of adrenal incidentalomas.
Spectrum bias in algorithms derived by artificial intelligence: a case study in detecting aortic stenosis using electrocardiograms
Shelly-Cohen, Michal, Attia, Itzhak Z, Friedman, Paul A. , Oh, Jae K. , López-Jiménez, Francisco , Lopez-Jimenez, Francisco , Tseng, Andrew S. , Attia, Itzhak Z, Noseworthy, Peter A.

Mayo Clinic

European Heart Journal - Digital Health | July 14, 2021 | Volume: 2 | Issue: 4 | Pages: 561-567

10.1093/ehjdh/ztab061 | PMID 36713099 Get It

Abstract Aims Spectrum bias can arise when a diagnostic test is derived from study populations with different disease spectra than the target population, resulting in poor generalizability. We used a real-world artificial intelligence (AI)-derived algorithm to detect severe aortic stenosis (AS) to experimentally assess the effect of spectrum bias on test performance. Methods and results All adult patients at the Mayo Clinic between 1 January 1989 and 30 September 2019 with transthoracic echocardiograms within 180 days after electrocardiogram (ECG) were identified. Two models were developed from two distinct patient cohorts: a whole-spectrum cohort comparing severe AS to any non-severe AS and an extreme-spectrum cohort comparing severe AS to no AS at all. Model performance was assessed. Overall, 258 607 patients had valid ECG and echocardiograms pairs. The area under the receiver operator curve was 0.87 and 0.91 for the whole-spectrum and extreme-spectrum models, respectively. Sensitivity and specificity for the whole-spectrum model was 80% and 81%, respectively, while for the extreme-spectrum model it was 84% and 84%, respectively. When applying the AI-ECG derived from the extreme-spectrum cohort to patients in the whole-spectrum cohort, the sensitivity, specificity, and area under the curve dropped to 83%, 73%, and 0.86, respectively. Conclusion While the algorithm performed robustly in identifying severe AS, this study shows that limiting datasets to clearly positive or negative labels leads to overestimation of test performance when testing an AI algorithm in the setting of classifying severe AS using ECG data. While the effect of the bias may be modest in this example, clinicians should be aware of the existence of such a bias in AI-derived algorithms.
Prevalence of Shoulder Arthroplasty in the United States and the Increasing Burden of Revision Shoulder Arthroplasty
Farley, Kevin X. , Wilson, Jacob M. , Kumar, Anjali , Gottschalk, Michael B. , Daly, Charles A. , Sánchez‐Sotelo, Joaquín , Daly, Charles , Wagner, Eric R , Sanchez-Sotelo, J. , Kumar, Anjali F , Wagner, Eric R.

Mayo Clinic

JBJS Open Access | July 14, 2021 | Volume: 6 | Issue: 3 | Pages: No page available

10.2106/jbjs.oa.20.00156 | PMID 34278185 Get It

Background: Existing data on the epidemiology of shoulder arthroplasty are limited to future projections of incidence. However, the prevalence of shoulder arthroplasty (the number of individuals with a shoulder arthroplasty alive at a certain time and its implications for the burden of revision procedures) remains undetermined for the United States. Hence, the purpose of this study was to estimate the prevalence of shoulder arthroplasty in the United States. Methods: The National Inpatient Sample (NIS) was queried to count all patients who underwent total shoulder arthroplasty (TSA), including both anatomic and reverse TSA, and hemiarthroplasty between 1988 and 2017. The counting method was used to calculate the current prevalence of TSA and hemiarthroplasty using age and sex-specific population and mortality data from the U.S. Census Bureau. Results: In 2017, an estimated 823,361 patients (95% confidence interval [CI], 809,267 to 837,129 patients) were living in the United States with a shoulder replacement. This represents a prevalence of 0.258%, increasing markedly from 1995 (0.031%) and 2005 (0.083%). Female patients had a higher prevalence at 0.294% than male patients at 0.221%. Over 2% of people who were ≥80 years of age in the United States were living with a shoulder replacement. Furthermore, approximately 60% of patients living with a shoulder replacement had undergone the operation between 2013 and 2017. The incidence of revision shoulder arthroplasty is increasing on an annual basis, with 10,290 revision procedures performed in 2017, costing the U.S. health-care system $205 million. Conclusions: The prevalence of shoulder arthroplasty in the United States has markedly increased over time. This trend will likely continue given increasing life expectancies and exponentially increasing shoulder arthroplasty incidence rates. Most patients do not have long-term follow-up, and revision shoulder arthroplasty rates are increasing, a trend that is projected to continue. The data from our study highlight the enormous public health impact of shoulder replacement and shed light on a potentially increasing revision burden.
In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
Albano, Mariana , Karau, Melissa J. , Greenwood‐Quaintance, Kerryl E. , Osmon, Douglas R. , Oravec, Caitlin P., Berry, Daniel J. , Patel, Robin , Patel, Robin , Berry, Daniel J , Abdel, Matthew P.

Mayo Clinic

Microbiology Spectrum | July 14, 2021 | Volume: 9 | Issue: 1 | Pages: No page available

10.1128/spectrum.00071-21 | PMID 34259553 Get It

Rifampin is an antibiotic with antistaphylococcal biofilm activity used in the management of staphylococcal periprosthetic joint infection with irrigation and debridement with component retention; some patients are unable to receive rifampin due to drug interactions or intolerance. We recently showed rifabutin and rifapentine to have in vitro activity against planktonic and biofilm states of rifampin-susceptible periprosthetic joint infection-associated staphylococci.
Using ensemble of ensemble machine learning methods to predict outcomes of cardiac resynchronization
Cai, Cheng , Zhang, Pei , Xiao, Peilin , Dai, Mingyan , Noseworthy, Peter A. , Friedman, Paul A. , Cha, Yong‐Mei , Zhang, Pei , Noseworthy, Peter A , Chen, Ming-Long , Cha, Yong-Mei , Cai, Cheng, Tafti, Ahmad P , Ngufor, Che , Liu, Hongfang

Mayo Clinic

Journal of Cardiovascular Electrophysiology | July 14, 2021 | Volume: 32 | Issue: 9 | Pages: 2504-2514

10.1111/jce.15171 | PMID 34260141 Get It

AbstractIntroductionThe efficacy of cardiac resynchronization therapy (CRT) has been widely studied in the medical literature; however, about 30% of candidates fail to respond to this treatment strategy. Smart computational approaches based on clinical data can help expose hidden patterns useful for identifying CRT responders.MethodsWe retrospectively analyzed the electronic health records of 1664 patients who underwent CRT procedures from January 1, 2002 to December 31, 2017. An ensemble of ensemble (EoE) machine learning (ML) system composed of a supervised and an unsupervised ML layers was developed to generate a prediction model for CRT response.ResultsWe compared the performance of EoE against traditional ML methods and the state‐of‐the‐art convolutional neural network (CNN) model trained on raw electrocardiographic (ECG) waveforms. We observed that the models exhibited improvement in performance as more features were incrementally used for training. Using the most comprehensive set of predictors, the performance of the EoE model in terms of the area under the receiver operating characteristic curve and F1‐score were 0.76 and 0.73, respectively. Direct application of the CNN model on the raw ECG waveforms did not generate promising results.ConclusionThe proposed CRT risk calculator effectively discriminates which heart failure (HF) patient is likely to respond to CRT significantly better than using clinical guidelines and traditional ML methods, thus suggesting that the tool can enhanced care management of HF patients by helping to identify high‐risk patients.
Lines of therapy before autologous stem cell transplant and CAR‐T affect outcomes in aggressive Non‐Hodgkin's lymphoma
Khurana, Arushi , Hathcock, Matthew , Habermann, Thomas M. , Gandhi, Sangeetha, Truong, Tuan, Ansell, Stephen M. , Inwards, David J. , Porrata, Luis F. , Johnston, Patrick B. , Micallef, Ivana N. , Lin, Yi , Paludo, Jonas , Ansell, Stephen M , Inwards, David J , Micallef, Ivana, Habermann, Thomas , Lin, Yi , Saleh, Abdullah S. Al , Bennani, N. Nora , Paludo, Jonas , Villasboas, José C.

Mayo Clinic

American Journal of Hematology | July 14, 2021 | Volume: 96 | Issue: 10 | Pages: No page available

10.1002/ajh.26293 | PMID 34260759 Get It